|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple sclerosis (MS) is a complex trait in which alleles at or near the class II loci HLA-DRB1 and HLA-DQB1 contribute significantly to genetic risk.
|
18606010 |
2008 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple sclerosis and neuromyelitis optica differ in their associations with DRB1*1501.
|
20591987 |
2010 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multiple sclerosis (MS) is a demyelinating disease associated with the HLA-DR2-related haplotype DRB1*1501, DQB1*0602 in Caucasoids and with DQB1*0602 in DR2-positive Cantonese.
|
8456441 |
1993 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1 typing was performed on 375 unrelated white patients with clinically definite MS and on 367 healthy controls.
|
11374095 |
2001 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*01-DQB1*0501 and DRB1*13-DQB1*0603 were negatively associated with MS in transmission disequilibrium test, but only the DRB1*13-DQB1*0603 association remained significant (P=0.008) after the elimination of DRB1*15-DQB1*0602 haplotypes.
|
11777553 |
2002 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA DRB1*04 was associated with IgM reactivity to MOG in MS patients, and DRB1*15 and DRB5 with anti-MOG IgA among asymptomatic relatives.
|
12458053 |
2002 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
DRB1*17 (P=0.00027) was clearly established as an MS susceptibility allele in addition to DRB1*15 (P<10(-14)).
|
15930013 |
2005 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
|
17531857 |
2007 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*01 and HLA-DRB1*10 do not interact with HLA-DRB1*17, implying that several mechanisms may be operative in major histocompatibility complex-associated MS susceptibility, perhaps analogous to the resistance alleles.
|
17845076 |
2007 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
DRB1*1501, DQB1*0602 and DQB1*0608 alleles were the only positive HLA association with MS.
|
18312478 |
2008 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-DRB1 is the major locus associated with risk for multiple sclerosis (MS).
|
18401352 |
2008 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*14 and DRB1*11 bearing haplotypes protect against MS and DRB1*01 and DRB1*10 interact with DRB1*15 to reduce risk of the disease.
|
18433881 |
2008 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
|
18656179 |
2008 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
DRB1*15 increased the risk of developing MS and HLA-A*02 decreased the risk.A*03 had no effect.
|
19482867 |
2009 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*15 (OR: 2.3; 95% CI: 1.68-3.07; p<0.001) and HLA-DQB1*06 (OR: 2.2; 95% CI: 1.54-3.07; p<0.001) groups as well as DRB1*1501 (OR: 2.6; 95% CI: 1.67-4.02; p<0.001), DRB1*1503 (OR: 2.2; 95% CI: 1.39-3.62; p=0.001) and DQB1*0602 (OR: 2.5; 95% CI: 1.66-3.71; p<0.001) alleles were found to be risk factors for MS.
|
19896562 |
2010 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-DRB1*1501 was the strongest risk allele in both primary progressive MS and relapsing-remitting MS.
|
20207784 |
2010 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*15 is associated with MS when comparing patients with unrelated healthy controls in a Spanish population.
|
20629714 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA DRB1*15 occurred most frequently in Donegal (greatest MS prevalence) and least frequently in South Dublin.
|
21248317 |
2011 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
DRB1*15 alleles confer increased susceptibility to pediatric-onset MS, supporting a fundamental similarity in genetic contribution to MS risk in both pediatric- and adult-onset disease.
|
21288988 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
DRB1*14 and DRB1*07 showed protective effects against MS in both groups (DRB1*14, allele group, Pc<0.00013, OR 0.53, 95%CI 0.42-0.66; phenotype group, Pc<0.00013, OR 0.57, 95%CI 0.45-0.71; DRB1*07, allele group, Pc<0.0026, OR 0.75, 95%CI 0.64-0.87; phenotype group, Pc<0.00013, OR 0.67, 95%CI 0.61-0.73).
|
21440682 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*01:01 is protective against developing MS; thus, a common genetic basis between IM and MS is not supported.
|
21482926 |
2011 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*15:01 and multiple sclerosis: a female association?
|
22127897 |
2012 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
DRB1 1501 and C. pneumoniae infection confer CSF IgG abnormality, while DRB1 0405 and H. pylori infection are positively and negatively associated with CSF IgG abnormality-negative MS, respectively, suggesting that genetic and environmental factors differentially contribute to MS susceptibility according to the CSF IgG abnormality status.
|
24736746 |
2014 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB1*15+ MS cases had more severe motor cortical parenchymal (P < 0.05), perivascular (P < 0.05) and meningeal (P < 0.05) T-cell inflammation compared to HLA-DRB1*15- cases.
|
24964187 |
2015 |
|
Multiple Sclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.
|
27237756 |
2016 |